Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 Next >
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Third Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Third Quarter 2023 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Reports Second Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Report Second Quarter 2023 Financial Results on August 1
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.